Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis

Yang Hu, Hao Nie, Hai Han Yu, Chuan Qin, LongJun Wu, Zhou Ping Tang, Dai Shi Tian

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple sclerosis. Results: Fifteen studies that collectively included 946 patients were selected for the meta-analysis. Rituximab therapy was associated with the mean annualized relapse rates decreasing by 0.80 (95% confidence interval, 0.45–1.15) and the mean Expanded Disability Status Scale score decreasing by 0.46 (95% confidence interval, 0.05–0.87). The likelihood of patients experiencing a relapse after starting rituximab therapy was only 15% (95% confidence interval, 7%–26%). Although mild-to-moderate adverse events occurred in 29.6% of the patients, there were no severe adverse events. Conclusions and relevance: This systematic review and meta-analysis shows that rituximab is associated with reduced annualized relapse rates and disability levels in patients with relapsing-remitting multiple sclerosis. It is also well tolerated and is not associated with serious adverse events.

Original languageEnglish (US)
JournalAutoimmunity Reviews
DOIs
StatePublished - Jan 1 2019

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Meta-Analysis
Safety
Confidence Intervals
Recurrence
Rituximab
Therapeutics

Keywords

  • Efficacy
  • Relapsing-remitting multiple sclerosis
  • Rituximab
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis : A systematic review and meta-analysis. / Hu, Yang; Nie, Hao; Yu, Hai Han; Qin, Chuan; Wu, LongJun; Tang, Zhou Ping; Tian, Dai Shi.

In: Autoimmunity Reviews, 01.01.2019.

Research output: Contribution to journalReview article

@article{05135f440b3044998156e992cee02e6c,
title = "Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis",
abstract = "Objective: To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple sclerosis. Results: Fifteen studies that collectively included 946 patients were selected for the meta-analysis. Rituximab therapy was associated with the mean annualized relapse rates decreasing by 0.80 (95{\%} confidence interval, 0.45–1.15) and the mean Expanded Disability Status Scale score decreasing by 0.46 (95{\%} confidence interval, 0.05–0.87). The likelihood of patients experiencing a relapse after starting rituximab therapy was only 15{\%} (95{\%} confidence interval, 7{\%}–26{\%}). Although mild-to-moderate adverse events occurred in 29.6{\%} of the patients, there were no severe adverse events. Conclusions and relevance: This systematic review and meta-analysis shows that rituximab is associated with reduced annualized relapse rates and disability levels in patients with relapsing-remitting multiple sclerosis. It is also well tolerated and is not associated with serious adverse events.",
keywords = "Efficacy, Relapsing-remitting multiple sclerosis, Rituximab, Safety",
author = "Yang Hu and Hao Nie and Yu, {Hai Han} and Chuan Qin and LongJun Wu and Tang, {Zhou Ping} and Tian, {Dai Shi}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.autrev.2019.03.011",
language = "English (US)",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

TY - JOUR

T1 - Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis

T2 - A systematic review and meta-analysis

AU - Hu, Yang

AU - Nie, Hao

AU - Yu, Hai Han

AU - Qin, Chuan

AU - Wu, LongJun

AU - Tang, Zhou Ping

AU - Tian, Dai Shi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple sclerosis. Results: Fifteen studies that collectively included 946 patients were selected for the meta-analysis. Rituximab therapy was associated with the mean annualized relapse rates decreasing by 0.80 (95% confidence interval, 0.45–1.15) and the mean Expanded Disability Status Scale score decreasing by 0.46 (95% confidence interval, 0.05–0.87). The likelihood of patients experiencing a relapse after starting rituximab therapy was only 15% (95% confidence interval, 7%–26%). Although mild-to-moderate adverse events occurred in 29.6% of the patients, there were no severe adverse events. Conclusions and relevance: This systematic review and meta-analysis shows that rituximab is associated with reduced annualized relapse rates and disability levels in patients with relapsing-remitting multiple sclerosis. It is also well tolerated and is not associated with serious adverse events.

AB - Objective: To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple sclerosis. Results: Fifteen studies that collectively included 946 patients were selected for the meta-analysis. Rituximab therapy was associated with the mean annualized relapse rates decreasing by 0.80 (95% confidence interval, 0.45–1.15) and the mean Expanded Disability Status Scale score decreasing by 0.46 (95% confidence interval, 0.05–0.87). The likelihood of patients experiencing a relapse after starting rituximab therapy was only 15% (95% confidence interval, 7%–26%). Although mild-to-moderate adverse events occurred in 29.6% of the patients, there were no severe adverse events. Conclusions and relevance: This systematic review and meta-analysis shows that rituximab is associated with reduced annualized relapse rates and disability levels in patients with relapsing-remitting multiple sclerosis. It is also well tolerated and is not associated with serious adverse events.

KW - Efficacy

KW - Relapsing-remitting multiple sclerosis

KW - Rituximab

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85062456412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062456412&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2019.03.011

DO - 10.1016/j.autrev.2019.03.011

M3 - Review article

C2 - 30844555

AN - SCOPUS:85062456412

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -